[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343670-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343670-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluation-of-targeted-alpha-therapy-using-211atfapi1-in-triple-negative-breast-cancer-xenograft-models","Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models","","Triple-negative breast cancer (TNBC) has limited therapeutic options and an unfavorable prognosis, motivating the development of targeted treatments. Fibroblast activation protein (FAP), expressed on cancer-associated fibroblasts, supports TNBC proliferation, migration, and invasion. This study evaluated theranostic performance by combining [18F]FAPI-74 PET imaging with targeted alpha therapy using [211At]FAPI1 in TNBC xenograft models. Mice xenografts were generated with MDA-MB-231 and HT1080 cells, and [18F]FAPI-74 accumulation validated FAP expression. A single dose of [211At]FAPI1 produced a significantly enhanced anti-tumor effect versus control. Results indicate [18F]FAPI-74 PET enables diagnosis of FAP expression, and [211At]FAPI1 shows promising therapeutic efficacy for TNBC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluation-of-targeted-alpha-therapy-using-211atfapi1-in-triple-negative-breast-cancer-xenograft-models/343670/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluation-of-targeted-alpha-therapy-using-211atfapi1-in-triple-negative-breast-cancer-xenograft-models/343670.png","ImageObject",300,407,{"name":42,"@type":43},"Skyler","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic strategy does the study evaluate in TNBC models?","Question",{"text":63,"@type":64},"The study evaluates targeted alpha therapy using [211At]FAPI1, aiming to deliver anti-tumor effects via alpha-particle emission through FAP targeting.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is FAP expression assessed prior to or alongside therapy?",{"text":68,"@type":64},"FAP expression is assessed using [18F]FAPI-74 PET imaging, with high tracer accumulation in MDA-MB-231 xenografts and pathological confirmation by immunostaining.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the key finding regarding treatment efficacy of [211At]FAPI1?",{"text":72,"@type":64},"Mice receiving [211At]FAPI1 (n = 11) showed a significantly enhanced anti-tumor effect compared with the control group (n = 7), with p = 0.002.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343670,1790869702,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nEvaluation of Targeted Alpha Therapy Using [211 At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models  \nKaori Abe 1, Tadashi Watabe 2,3, *, Kazuko Kaneda-Nakashima 3,4, Yoshifumi Shirakami 3, Yuichiro Kadonaga 3, Sadahiro Naka 5, Kazuhiro Ooe 3, Atsushi Toyoshima 3, Frederik Giesel 3,6, Takeshi Usui 1, Nanae Masunaga 1, Chieko Mishima 1, Masami Tsukabe 1, Tetsuhiro Yoshinami 1, Yoshiaki Sota 1, Tomohiro Miyake 1, Tomonori Tanei 1, Masafumi Shimoda 1 and Kenzo Shimazu 1  \nCitation: Abe, K.; Watabe, T.;  \nKaneda-Nakashima, K.;  \nShirakami, Y.; Kadonaga, Y.; Naka, S.; Ooe, K.; Toyoshima, A.; Giesel, F.; Usui, T.; et al. Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models. Int. J. Mol. Sci. 2024, 25, 11567. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms252111567](10.3390/ijms252111567)  \nAcademic Editor: Christos Papadimitriou  \nReceived: 14 September 2024  \nRevised: 14 October 2024  \nAccepted: 24 October 2024  \nPublished: 28 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan; [abe216@onsurg.med.osaka-u.ac.jp](abe216@onsurg.med.osaka-u.ac.jp) (K.A.)  \n2 Department of Radiology, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan  \n3 Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan  \n4 Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Medicine, Osaka University, Suita 560-0043, Japan  \n5 Department of Pharmacy, Osaka University Hospital, Suita 565-0871, Japan  \n6 Department of Nuclear Medicine, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University, 40225 Duesseldorf, Germany  \n* [Correspondence: watabe.tadashi.med@osaka-u.ac.jp](Correspondence: watabe.tadashi.med@osaka-u.ac.jp); Tel.: +81-6-6879-3434  \nAbstract: Triple-negative breast cancer (TNBC) presents limited therapeutic options and is associated with poor prognosis. Early detection and the development of novel therapeutic agents are therefore imperative. Fibroblast activation protein (FAP) is a membrane protein expressed on cancer-associated ﬁbroblasts (CAFs) that plays an essential role in TNBC proliferation, migration, and invasion. Consequently, it is hypothesized that the Astatine (211At)-labeled FAP inhibitor (FAPI) selectively exerts anti-tumor effects through alpha-particle emission. In this study, we aimed to assess its theranostic capabilities by integrating [18F]FAPI-74 PET imaging with targeted alpha therapy using [211At]FAPI1 in TNBC models. Mice xenografts were established by transplanting MDA-MB-231 and HT1080 cells (control) . As a parallel diagnostic method,[18F]FAPI-74 was administered for PET imaging to validate FAP expression. A single dose of [211At]FAPI1 (1 .04 􀀆 0. 10 MBq) was administered to evaluate the therapeutic efﬁcacy. [18F]FAPI-74 exhibited high accumulation in MDA-MB-231 xenografts, and FAP expression was pathologically conﬁrmed via immunostaining. The group that received [211At]FAPI1 (n = 11) demonstrated a signiﬁcantly enhanced anti-tumor effect compared with the control group (n = 7) (p = 0 .002) . In conclusion,[18F]FAPI-74 PET imaging was successfully used to diagnose FAP expression, and as [211At]FAPI1 showed promising therapeutic efﬁcacy in TNBC models, it is expected to be a viable therapeutic option.  \nKeywords: triple-negative breast cancer; FAP; CAF; FAPI-PET; Astatine (211At); 􀀋-emitting nuclides;[211At]FAPI1; theranostics  \n1. Introduction  \nAt present, breast cancer is the most preva","cbCailT7kQGfDuc4","https://ap.wps.com/l/cbCailT7kQGfDuc4","pdf",3138058,12,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What therapeutic strategy does the study evaluate in TNBC models?\",\"answer\":\"The study evaluates targeted alpha therapy using [211At]FAPI1, aiming to deliver anti-tumor effects via alpha-particle emission through FAP targeting.\"},{\"question\":\"How is FAP expression assessed prior to or alongside therapy?\",\"answer\":\"FAP expression is assessed using [18F]FAPI-74 PET imaging, with high tracer accumulation in MDA-MB-231 xenografts and pathological confirmation by immunostaining.\"},{\"question\":\"What is the key finding regarding treatment efficacy of [211At]FAPI1?\",\"answer\":\"Mice receiving [211At]FAPI1 (n = 11) showed a significantly enhanced anti-tumor effect compared with the control group (n = 7), with p = 0.002.\"}]","Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models | PDF",1790051750,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec94e7657be8022a6cd9b1ef3e133972.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3fc13ac83b67d164abcd2207e3cea41f.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6fdd554702b237abf3b1cf05cd060b5d.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/912bcf34fb3a053f333248783514c8bb.webp",980,1385]